myasthenia gravis

Aug 20, 2020

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) lett...

Nov 07, 2019

Switzerland-based Vifor Pharma and Germany-based Evotech AG have collaborated for the development and discovery of new treatments for kidney diseases. The launch of a new 50:50 joint venture will be focused on developing nephrology pipeline utilizing Evotec’s UK kidney biobank, NURTuRE. Under the terms of the a...

Jun 28, 2019

Myasthenia gravis (MG) is an autoimmune syndrome that causes weakness in the skeletal muscles caused due to the failure of neuromuscular transmission. Communication between nerve cells and muscles becomes hampered, thus preventing crucial muscles from contracting. This impairment in results from the binding of auto...

Jun 28, 2019

Myasthenia Gravis June is Myasthenia Gravis Awareness Month. Myasthenia gravis is a disorder causing weakness and easy fatigue of voluntary muscles. It is caused by a breakdown in the communication between nerves and muscles, usually because of an immunological problem.

Feb 04, 2019

https://www.slideshare.net/DelveInsight/myasthenia-gravis-126250701?qid=b9adbccf-6d91-4e5e-84e1-7603c87a029e&v=&b=&from_search=1 Myasthenia gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved i...

Mar 28, 2018

Novo Holdings optimistic about investments in life sciences Novo Holdings is planning to increase its investment in early & late stage biotechs. Its focus will be mainly in the U.S. and Europe. They are optimistic about the investment in life-science companies with their past experience. NMD gets USD 47 million...